Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead Offers Split Guidance For HCV; Expects Further Decline In 2017

Feb 08 2017

• By Joseph Haas

Global currency

Related Content

Gilead Coming To The End Of HCV Road With Triple-Drug Regimen

Nov 02 2016

Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos

Nov 02 2016

Gilead Sees Prospects For Declining HCV Revenues To Stabilize

Jul 28 2016

Related Companies

Gilead Sciences, Inc.

AbbVie Inc.

Merck & Co., Inc.

Additional Topics

Sales & Earnings Commercial Infectious Diseases BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.